Tesetaxel Every 3 Weeks vs Weekly vs Capecitabine as 1st-line Therapy for Locally Advanced or Metastatic Breast Cancer
Study Details
Study Description
Brief Summary
This study is being conducted to compare the efficacy and safety of tesetaxel administered once every 3 weeks in a 21-day cycle, tesetaxel administered once weekly for 3 consecutive weeks in a 28-day cycle, and capecitabine administered twice daily for 14 consecutive days in a 21-day cycle.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 2 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Tesetaxel every 3 weeks Tesetaxel 27 mg/m2 orally on Day 1 in a 21-day cycle |
Drug: Tesetaxel
Tesetaxel 27 mg/m2 orally once on Day 1 of each 21-day cycle
|
| Experimental: Tesetaxel weekly Tesetaxel 15 mg/m2 orally once every 7 days for 3 consecutive weeks on Day 1, Day 8, and Day 15 in a 28-day cycle |
Drug: Tesetaxel
Tesetaxel 15 mg/m2 orally once every 7 days for 3 consecutive weeks on Day 1, Day 8, and Day 15 of each 28-day cycle
|
| Active Comparator: Capecitabine Capecitabine 1250 mg/m2 orally twice daily (equivalent to a total daily dose of 2500 mg/m2) on Day 1 through Day 14 in a 21-day cycle |
Drug: Capecitabine
Capecitabine 1250 mg/m2 orally twice daily (in the morning and evening after a meal; equivalent to a total daily dose of 2500 mg/m2) on Day 1 through Day 14 of each 21-day cycle
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Response rate [4 months after the date of randomization of the last patient, which is estimated will occur 16 months after the first patient is randomized]
the percentage of patients with a confirmed complete or partial response, as defined in the revised Response Evaluation Criteria in Solid Tumors (revised RECIST [Version 1.1])
Secondary Outcome Measures
- Clinical benefit rate [12 months after the date of randomization of the last patient, which is estimated will occur 24 months after the first patient is randomized]
the percentage of patients with a complete or partial response of any duration or stable disease lasting ≥ 6 months
- Progression-free survival [12 months after the date of randomization of the last patient, which is estimated will occur 24 months after the first patient is randomized]
the period from the date of randomization to the date when disease progression is first documented or when the patient dies within 6 weeks of the last lesion assessment
- Progression-free survival rate [6 and 12 months after patients' date of randomization]
the percentage of patients who are progression free
- Adverse events [up to 30 days after patients' last dose of study medication]
the percentage of patients with adverse events classified by term and body system
Eligibility Criteria
Criteria
Key inclusion criteria:
-
Female
-
At least 18 years of age
-
Locally advanced non-resectable or metastatic breast cancer
-
HER2 negative disease
-
Measurable disease per revised RECIST, Version 1.1
-
Eastern Cooperative Oncology Group performance status 0 or 1
-
Chemotherapy naïve, OR 1 prior chemotherapy regimen in the neoadjuvant or adjuvant setting provided the patient has had a disease-free interval of ≥ 12 months after ending this chemotherapy. If the neoadjuvant or adjuvant chemotherapy included a taxane, ≥ 2 years must have passed since this treatment ended.
-
Documented disease recurrence or progression
-
Adequate bone marrow, hepatic, and renal function
-
Ability to swallow an oral solid-dosage form of medication
-
Written informed consent
Key exclusion criteria:
-
Known metastasis to the central nervous system
-
Other cancer within the preceding 5 years other than curatively treated basal or squamous cell carcinoma of the skin or carcinoma of the cervix in situ
-
Significant medical disease other than breast cancer
-
Presence of neuropathy > Grade 1 (NCI CTC)
-
History of hypersensitivity to a taxane or capecitabine, other fluoropyrimidine agents, or any of their ingredients
-
History of severe or unexpected reaction to fluoropyrimidine therapy
-
Need to continue any regularly-taken medication that is a potent inhibitor or inducer of the CYP3A pathway
-
Less than 2 weeks since use of a medication or ingestion of an agent, beverage, or food that is a potent inhibitor or inducer of the CYP3A pathway
-
Known dihydropyrimidine dehydrogenase deficiency
-
Pregnancy or lactation
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | The West Clinic | Memphis | Tennessee | United States | 38120 |
Sponsors and Collaborators
- Genta Incorporated
Investigators
- Principal Investigator: Andrew D Seidman, MD, Memorial Sloan Kettering Cancer Center
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- TOB206